This paper is only available as a PDF. To read, Please Download here.
Abstract
Controversy surrounds the use of models in economic evaluations of pharmaceuticals.
Many believe that modeling is a way of manipulating results and is not credible, whereas
others consider modeling a valuable tool in economic evaluations. The purpose of this
article is to provide a historical perspective on modeling, focus on the controversy
and policy implications of using models, and review the suggested framework and guidelines
for modeling practices. Models can be used to extrapolate beyond intermediate end
points, predict costs and consequences of alternative therapies, generalize data to
other settings, pose questions instead of providing answers when no data exist, design
an evaluation to reduce uncertainty, and perform direct comparisons that are not currently
available. We believe that a useful model should document the detailed inner workings,
assumptions, and inherent bias during production (and at publication time), so that
its reviewers and users can evaluate the appropriateness of the model's outcomes.
The acceptability of models in the future rests with the researchers constructing
them. If constructed appropriately, modeling economic evaluations is not a manipulation
but rather a valuable tool.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy.Health Econ. 1997; 6: 589-601
- Problems of using modelling in the economic evaluation of health care.Health Econ. 1996; 5: 1-11
- The journal's policy on cost-effectiveness analysis.NEJM. 1994; 331 (Editorial): 669-670
- Guidelines for authors and peer reviewers of economic submissions to the BMJ.BMJ. 1996; 313: 275-283
- Health and economic outcomes modeling practices: A suggested framework.Value Health. 1998; 1: 131-147
- Modelling in economic evaluation: An unavoidable fact of life.Health Econ. 1997; 6: 217-227
- Cost-effectiveness of cholesterollowering: Results from the Scandinavian Simvastatin Survival Study.Eur Heart J. 1996; 17: 1001-1007
- Validating literature-based models with direct clinical trial results: The costeffectiveness of secondary prophylaxis for PCP in AIDS patients.Med Decis Mak. 1996; 16: 29-35
- The future of pharmacoeconomics: Bridging science and practice.Clin Ther. 1996; 18: 969-978
- Issues in the cross-national assessment of health technology.Int J Technol Assess Health Care. 1992; 8: 671-682
- The swine-influenza decision.NEJM. 1976; 295: 759-765
- Economic evaluation in health care research and development: Undertake it early and often.in: HERG Discussion Paper No. 12. Brunel University, Uxbridge, UK1995
- Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision analytic model.Circulation. 1994; 89: 1859-1874
- Policy implications of modeling the cost-effectiveness of health care technologies.Drug Inf J. 1995; 29: 1469-1475
- Allocation of resources to manage hypertension.NEJM. 1977; 296: 732-739
- Foundation of costeffectiveness analysis for health and medical practices.NEJM. 1977; 296: 716-721
- Update of Federal Activities Regarding the Use of Pneumococcal Vaccine. US Government Printing Office, Washington, DC1994
- Costeffectiveness of vaccination against pneumococcal pneumonia.NEJM. 1980; 303: 553-559
- Screening of Cancer: Theory, Analysis, and Design. Prentice Hall, Englewood Cliffs, NJ1980
- Methds used to quit smoking in the United States: Do cessation programs help?.JAMA. 1990; 263: 2760-2765
- Effectiveness of smoking control strategies.MMWR Morb Mortal Wkly Rep. 1992; 41: 645-647
- Effectiveness of smoking control strategies.MMWR Morb Mortal Wkly Rep. 1992; 41: 653
- Screening mammography in women aged 40–49 years: Analysis of cost-effectiveness.Radiology. 1994; 191: 647-650
- Cost-benefit analysis of preconception care for women with established diabetes mellitus.Diabetes Care. 1993; 16: 1146-1157
- Effects of intravenous magnesium in suspected acute myocardial infarction: Overview of randomized trials.BMJ. 1991; 303: 1499-1503
- ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction.Lancet. 1995; 345: 669-685
- Zidovudine in asymptomatic HIV virus infection. A controlled trial in persons with fewer than 500 CD4-positive Cells per cubic millimeter.NEJM. 1990; 322: 941-949
- Preliminary analysis of the Concorde trial.Lancet. 1993; 341: 889-890
- Economic evaluation of osteoporosis prevention.Health Policy. 1993; 24: 103-124
- Improved observational method for studying therapeutic efficacy: Suggestive evidence that lidocaine prophylaxis prevents death in acute myocardial infarction.JAMA. 1981; 246: 2455-2459
- Metaanalytic evidence against the prophylactic use of lidocaine in acute myocardial infarction.Arch Intern Med. 1989; 149: 2694-2698
- Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.NEJM. 1991; 324: 1362-1365
- Decision analysis in obstetrics and gynaecology.Bailliere's Clin Obstet Gynaecol. 1990; 4: 857-866
- A report on principles. Task Force on Principles for Economic Analysis of Health Care Technology.Ann Intern Med. 1995; 123: 61-70
- Reporting guidelines for economic studies.Health Econ. 1995; 4: 85-94
- (Draft)Principles for the Review of Pharmacoeconomic Promotion. Food and Drug Administration, Rockville, Md1995
- Recommendation of the Panel of CostEffectiveness in Health and Medicine.JAMA. 1996; 276: 1253-1258
- Kannell WB Woolf PA Garrison RJ The Framingham Study: An Epidemiolog-ical Investigation of Cardiovascular Disease. Publication NIH 87-2703. US Public Health Service, Bethesda, Md1987
- A coronary primary prevention study of Scottish men aged 45–65 years trial design.J Clin Epidemiol. 1992; 45: 849-860
- Decision analytic modelling: Some uses in the evaluation of new pharmaceuticals.Drug Inf J. 1994; 28: 691-707
- Uncertainty in economic evaluation of health care technologies: The role of sensitivity analysis.Health Econ. 1994; 308: 283-284
- Problems and perspectives on the use of decision-analysis models for prostate cancer.J Urol. 1994; 152 (5 pt 2): 1888-1893
Article info
Publication history
Accepted:
March 12,
1999
Identification
Copyright
© 1999 Published by Elsevier Inc.
